CompaniesAdvaxis

Advaxis

defunct

About

Defunct Company

Areas of Focus

Categories

Bankrupt, Merged, Sold, Renamed or Otherwise Defunct

Clinical Trials (13)

Total Trials

13

As Lead Sponsor

10

As Collaborator

3

Total Enrollment

484

By Phase

PHASE1/PHASE2: 4PHASE2: 5PHASE1: 3PHASE3: 1

By Status

COMPLETED: 7TERMINATED: 5WITHDRAWN: 1

Clinical Trials Pipeline13 trials

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Phase 1/2

Phase 2/3

N/A

Phase

Status

Role

Condition

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

Today

Hover over trial bars to see details

Recent Trials

NCT03847519Lead Sponsor

Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer

PHASE1/PHASE2Completed

24 participants

Started: Feb 12, 2019 · Completed: Feb 22, 2022

NCT02531854Lead Sponsor

A Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients With Human Papillomavirus Positive (HPV+), NSCLC Following First-Line Induction Chemotherapy

PHASE2Withdrawn

Started: Dec 31, 2018 · Completed: Mar 31, 2019

NCT03265080Lead Sponsor

A Study of ADXS-NEO Expressing Personalized Tumor Antigens

PHASE1Terminated

13 participants

Started: Mar 28, 2018 · Completed: Nov 12, 2020

NCT02399813Lead Sponsor

A Phase 2 Study of Axalimogene Filolisbac (ADXS11-001) in Participants With Carcinoma of the Anorectal Canal

PHASE2Completed

36 participants

Started: Jun 2, 2016 · Completed: Jan 3, 2019

NCT02853604Lead Sponsor

Study of ADXS11-001 in Participants With High Risk Locally Advanced Cervical Cancer

PHASE3Terminated

110 participants

Started: Dec 15, 2015 · Completed: Jul 31, 2019

View all 13 trials →

Funding History (20)

8-K/A

Apr 19, 2024

8-K

Apr 3, 2024

8-K

Mar 29, 2024

DEFM14C

Mar 5, 2024

8-K

Mar 5, 2024

8-K

Feb 23, 2024

8-K

Feb 9, 2024

8-K

Feb 6, 2024

8-K/A

Jan 3, 2024

D

Nov 2, 2023

Related Companies

Ayala Pharmaceuticals

merged